Allergic Rhinitis Clinical Trial
Official title:
Evaluation of Nasal Mucosal Permeability in Controls and House Dust Mite Allergic Rhinitis Patients
Recently, a critical role in the development of allergic rhinitis (AR) has been attributed
to the nasal epithelium. The airway epithelium forms a physical barrier, protecting the
nasal mucosa and underlying organs from damage from contact with exogenous particles. The
nasal epithelial barrier is primarily determined by the integrity of the airway epithelium,
in which epithelial cells are connected to each other by complex network structures like
tight junctions (TJs), ultimately sealing off the paracellular space. TJs consist of
different transmembrane proteins including occludin, tricellulin, the claudin family, and
junctional adhesion molecules. TJ form intercellular homodimers/heterodimers between
neighboring cells. Scaffold adaptor proteins like cingulin and the zonula occludens family
connect the transmembrane proteins to the actin cytoskeleton.
Disturbed TJ function can facilitate the entrance of foreign pathogens and antigens into the
submucosal layer, giving raise to allergic sensitization via increased access of allergens
to the dendritic cells and/or inducing persistent inflammation via activation of mast cells
and other inflammatory cells residing in the upper airways. Chronic disorders like allergic
asthma, inflammatory bowel disease and atopic dermatitis have been linked to defective or
altered TJ function. Recently, an impaired epithelial barrier function was found in patients
with chronic rhinosinusitis with nasal polyps (CRSwNP), suggesting changes in TJ arrangement
in the nasal cavity. CRSwNP presents a similar inflammation of the sinonasal cavities as
found in AR patients, i.e. a Th2 cytokine driven inflammation with tissue eosinophilia.
Nevertheless, the role of TJs and its regulation has not been investigated in AR.
n/a
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05080322 -
Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis
|
Phase 4 | |
Recruiting |
NCT06028490 -
A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.
|
Phase 2 | |
Completed |
NCT04388358 -
Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation
|
N/A | |
Recruiting |
NCT04202263 -
Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline
|
Phase 2 | |
Completed |
NCT04078009 -
Standardising Nasal Allergen Challenge in Adult With Hay Fever
|
N/A | |
Completed |
NCT03644680 -
Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study
|
N/A | |
Completed |
NCT04541004 -
Adolescent Mite Allergy Safety Evaluation
|
Phase 3 | |
Recruiting |
NCT05378594 -
HDM and Silver Birch NAC Standardisation
|
N/A | |
Not yet recruiting |
NCT05684380 -
Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
|
Phase 3 | |
Not yet recruiting |
NCT01014325 -
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
|
Phase 3 | |
Completed |
NCT02910401 -
Clinical Response to Rhinovirus Challenge
|
Phase 2 | |
Completed |
NCT02943720 -
ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen
|
Phase 2 | |
Completed |
NCT02556801 -
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
|
Phase 2 | |
Not yet recruiting |
NCT02233426 -
Effect of Hypertonic Solutions on Allergic Rhinitis Patients
|
N/A | |
Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
Completed |
NCT01946035 -
Alpha-Blockers in Allergic Rhinitis (MAN 01)
|
Phase 4 | |
Completed |
NCT01918956 -
PURETHAL Birch RUSH Study
|
Phase 4 | |
Completed |
NCT01682070 -
SUBLIVAC FIX Phleum Pratense DT/DRF
|
Phase 2 | |
Recruiting |
NCT01454492 -
The Relationship Between Allergic Rhinitis and Geographic Tongue
|
N/A | |
Completed |
NCT01438463 -
PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
|
Phase 2 |